Novo Nordisk shares pop 10% on early-stage weight loss drug trial results

A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.

Tom Little | Reuters

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.

Shares were last up 9.5% at 11:02 a.m. London time.

This is a developing story. Please check back for updates.

Source

World

Venture Global closes below IPO price in disappointing debut despite Trump’s support of LNG industry

January 24, 2025

Natural gas exporter Venture Global shares fell 4% in its first day of trading, as the company looked to test investor appetite for energy stocks amid the Trump administration efforts to implement a sweeping agenda aimed at boosting oil and gas production. “The Trump administration has made very clear they support growing LNG exports,” Venture […]

World

Megacaps lead a major week of earnings as traders seek clarity on the state of the bull market

January 24, 2025

The Magnificent Seven companies reporting in the week ahead could unlock the next leg of the rally, as investors bet that earnings growth fueled by artificial intelligence could power a market some worry has gone to excess. The Federal Reserve will also hold its January meeting, with key inflation data coming Friday. Four out of […]

World

These companies have earnings momentum heading into their quarterly reports next week

January 24, 2025

Some companies reporting earnings next week have forward earnings momentum that investors may be able to ride. Next week will be busy for fourth-quarter earnings, with 90 companies in the S & P 500 index — and eight members of the Dow Jones Industrial Average — on the docket to report quarterly results. With companies […]